Literature DB >> 8973221

Heart attacks and homocysteine.

I Graham, R Meleady.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8973221      PMCID： PMC2353008          DOI： 10.1136/bmj.313.7070.1419

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians.

Authors:  M J Stampfer; M R Malinow; W C Willett; L M Newcomer; B Upson; D Ullmann; P V Tishler; C H Hennekens
Journal:  JAMA       Date:  1992-08-19       Impact factor: 56.272

2.  Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences?

Authors:  L Daly; K Robinson; K S Tan; I M Graham
Journal:  Q J Med       Date:  1993-10

3.  Serum total homocysteine and coronary heart disease.

Authors:  E Arnesen; H Refsum; K H Bønaa; P M Ueland; O H Førde; J E Nordrehaug
Journal:  Int J Epidemiol       Date:  1995-08       Impact factor: 7.196

4.  Homocysteine theory of arteriosclerosis.

Authors:  K S McCully; R B Wilson
Journal:  Atherosclerosis       Date:  1975 Sep-Oct       Impact factor: 5.162

5.  Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people.

Authors:  E Joosten; A van den Berg; R Riezler; H J Naurath; J Lindenbaum; S P Stabler; R H Allen
Journal:  Am J Clin Nutr       Date:  1993-10       Impact factor: 7.045

6.  Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease.

Authors:  L L Wu; J Wu; S C Hunt; B C James; G M Vincent; R R Williams; P N Hopkins
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

7.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.

Authors:  A M Engbersen; D G Franken; G H Boers; E M Stevens; F J Trijbels; H J Blom
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

8.  Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease.

Authors:  K Robinson; E L Mayer; D P Miller; R Green; F van Lente; A Gupta; K Kottke-Marchant; S R Savon; J Selhub; S E Nissen
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

9.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.

Authors:  J Selhub; P F Jacques; P W Wilson; D Rush; I H Rosenberg
Journal:  JAMA       Date:  1993-12-08       Impact factor: 56.272

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272
View more
  6 in total

1.  Similarities in the epidemiology of neural tube defects and coronary heart disease: is homocysteine the missing link?

Authors:  D H Stone; P McCarron; G D Smith
Journal:  J Epidemiol Community Health       Date:  1999-12       Impact factor: 3.710

Review 2.  Cobalamin status in children.

Authors:  Anne-Lise Bjørke-Monsen; Per Magne Ueland
Journal:  J Inherit Metab Dis       Date:  2010-05-27       Impact factor: 4.982

3.  An audit of the investigation and treatment of folic acid deficiency.

Authors:  N Haslam; C S Probert
Journal:  J R Soc Med       Date:  1998-02       Impact factor: 5.344

4.  Cardiovascular risk in women with polycystic ovarian syndrome (PCOS).

Authors:  A S T Bickerton; N Clark; D Meeking; K M Shaw; M Crook; P Lumb; C Turner; M H Cummings
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

5.  Evaluation of Oxidative Stress and hsCRP in Polycystic Ovarian Syndrome in a Tertiary Care Hospital.

Authors:  N Unni C Sumithra; R Lakshman Lakshmi; N Leela Menon; K N Subhakumari; V S Sheejamol
Journal:  Indian J Clin Biochem       Date:  2014-04-06

6.  Does folate therapy reduce the risk of coronary restenosis?

Authors:  E S van Hattum; P A Doevendans; F L Moll
Journal:  Neth Heart J       Date:  2007-01       Impact factor: 2.380
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.